Optimization of meropenem dosage in the critically ill population based on renal function

Intensive Care Medicine

Volumn 37, Issue 4, 2011, Pages 632-638

  Crandon, Jared L ^a   Ariano, Robert E ^b   Zelenitsky, Sheryl A ^b   Nicasio, Anthony M ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Creatinine clearance; Meropenem; Monte Carlo simulation; Population pharmacokinetics; Prolonged infusion

Indexed keywords

MEROPENEM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; CRITICAL ILLNESS; FEMALE; HUMAN; INTENSIVE CARE; KIDNEY FUNCTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CONNECTICUT; CREATININE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITALS, URBAN; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MONTE CARLO METHOD; THIENAMYCINS;

EID: 79953811686     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-010-2105-0     Document Type: Article

References (25)

1. Merrem (2007) (Meropenem) package insert. AstraZeneca, Wilmington
2. Li C, Kuti JL, Nightingale CH, Nicolau DP (2006) Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46:1171-1178 (Pubitemid 44387417)
3. Clinical Laboratory Standard Institute (2008) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI Publication M07-A8, Wayne
4. DeRyke CA, Kuti JL, Nicolau DP (2007) Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 58:337-344 (Pubitemid 47017635)
5. Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T (2008) Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid. J Infect Chemother 14:330-332
6. Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2:289-300
7. Turnidge JD (1998) The pharmacodynamics of beta-lactams. Clin Infect Dis 27:10-22
8. Eggimann P, Pittet D (2001) Infection control in the ICU. Chest 120:2059-2093 (Pubitemid 34053475)
9. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851 quiz 859
10. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA (2001) Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 45:13-22 (Pubitemid 32039087)
11. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL (2009) Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 25:69-77
12. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J (2009) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64:142-150
13. Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F (1996) High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl 686:19-26 (Pubitemid 26382454)
14. Leary RJ, Schumitzky A, Van Guilder M (2001) An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings, fouteenth IEEE symposium on computer-based medical systems. IEEE Computer Society, Bethesda, pp 389-394
15. Crandon JL, Kuti JL, Jones RN, Nicolau DP (2009) Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother 43:220-227
16. Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA (2002) Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 19:105-110 (Pubitemid 34168176)
17. Krueger WA, Bulitta J, Kinzig- Schippers M, Landersdorfer C, Holzgrabe U, Naber KG, Drusano GL, Sorgel F (2005) Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 49:1881-1889 (Pubitemid 40631603)
18. Lee DG, Choi SM, Shin WS, Lah HO, Yim DS (2006) Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 28:333-339
19. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR (2005) Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 44:539-549 (Pubitemid 40733738)
20. Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H (1999) Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43:523-527 (Pubitemid 29182302)
21. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C (1999) Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 55:1878-1884 (Pubitemid 29197975)
22. Lipman J, Wallis SC, Boots RJ (2003) Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 97:1149-1154 (table of contents)
23. Chow KM, Hui AC, Szeto CC (2005) Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 24:649-653 (Pubitemid 41670564)
24. Bulik CC, Quintiliani Jr R, Samuel Pope J, Kuti JL, Nicolau DP (2009) Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis - a review of 3 cases. Resp Med CME E pub
25. Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725-1730 (Pubitemid 46744151)